Search for: "In re Kao" Results 21 - 40 of 52
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
17 Jun 2008, 10:23 pm
Cassin is now changing her story, she is not a Doe defendant in this case and has no basis to assert a res judicata defense. [read post]
16 Jun 2017, 6:02 am by Lawrence B. Ebert
”); Inre Kao, 639 F.3d 1057, 1067 (Fed. [read post]
13 Jun 2011, 9:26 am by By Erik Lundegaard
They're dealing with so many things: the personal loss of a family member; the estate issues; tax issues and sometimes liquidity issues; and also personal issues within the family. [read post]
25 May 2011, 4:59 am by Marie Louise
  Highlights this week included: District Court Delaware grants TRO against Mylan’s generic Amrix, after finding patents invalid: In Re Cyclobenzaprine Hyldrochloride Extended-Release Capsule Patent Litigation (Orange Book Blog) (Patent Docs)   Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
15 Feb 2010, 9:21 am
So if you're a golfer, or maybe a wannabe golfer like me, think about participating. [read post]
7 May 2009, 7:16 am by Dean
So if you're a golfer, or maybe a wannabe golfer like me, think about participating. [read post]
27 Jul 2009, 1:45 pm
That’s how we got to where we’re at now. [read post]
30 Apr 2018, 6:39 am by scottgaille
  Instead, the fox indirectly causes the counter-party to become the proponent of the fox’s compromise—so the counter-party gains face (kao o tateru). [read post]
17 Jun 2008, 4:00 am
As much as civil liberties remain under assault in the United States -- with it being essential constantly to refight and re-win  previous civil liberties victories --  plenty of dissident actions that would get little if any suppression in the United States routinely get suppressed in Singapore. [read post]
18 May 2011, 12:33 am by Marie Louise
Du Pont (EPLAW) Opana (Oxymorphone) – US: CAFC: important decision controlling BPAI obviousness holdings: In re Kao (Patently-O) (PharmaPatents) Silenor (Doxepin) – US: Somaxon sues Actavis over application to market generic Silenor (GenericsWeb) Tanakan (Ginko Biloba) – France: Mylan ordered to pay €17M to Ipsen for unfair competition by marketing Vitalogink to pharmacists as an “equivalent” to Tanakan (EPLAW) Valcyte (Valganciclovir) – US:… [read post]
18 Dec 2011, 1:06 pm
" In re Kao, 639 F.3d 1057, 1068 (Fed. [read post]
26 Feb 2016, 9:06 am by Lawrence B. Ebert
., 683 F.3d at 1363;see also In re Huai-Hung Kao, 639 F.3d 1057, 1068 (Fed.Cir. 2011) (“Where the offered secondary considerationactually results from something other than what is bothclaimed and novel in the claim, there is no nexus to themerits of the claimed invention. [read post]
2 Dec 2009, 2:03 am by charonqc
We’re all extraordinary. [read post]